VBI-1901: AACR 2020 Webcast

By June 22, 2020August 26th, 2020No Comments

David E. Anderson, Ph.D., discusses updated Part B data from the VBI’s ongoing Phase 1/2a study of VBI-1901, the company’s cancer vaccine immunotherapeutic, with Allen Waziri, M.D., CEO and Co-Founder, iCE Neurosystems, Former Director of the Brain Tumor Program at Inova Neuroscience Institute, and member of VBI’s GBM/Immuno-Oncology Scientific and Clinical Advisory Board.